LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    Achieving the Potential of Genome Editing: the Perspective of the European Biotech Industry

    25/06/2019
    POSITION PAPER

    Achieving the Potential of Genome Editing: the Perspective of the European Biotech Industry

    The European Union has a unique opportunity to create headroom for innovation and continued investment for the future by fostering and guiding forward a major scientific breakthrough - genome editing.

    Genome editing is an umbrella term for a range of tools that enable changes at targeted sites in the genome of an organism. Applied worldwide by researchers in academia, governmental research institutions and industry, these innovations represent a promising next step in research towards beneficial uses in medicine, agriculture and the bio-economy aimed at addressing some of society’s grand challenges.

    While researchers, academia, industry and regulatory authorities have in-depth understanding of genome editing in terms of the underlying science and resulting benefits and challenges, this knowledge has not yet been fully passed on to the general public.

    To help respond to this need, EuropaBio, the voice of the biotech industry, has developed this paper to bring the latest views from the developers and users of genome editing tools and applications.

    Public engagement and proportionate regulatory policies would help ensure that Europe, together with the rest of the world, can reap the great societal and economic benefits that genome editing can bring.

    EuropaBio calls upon European decision-makers to create platforms to ensure consumer confidence and to provide regulatory clarity to enable innovation for developing products by genome editing methods. To this end, EuropaBio calls for:

    ■ an inclusive, fact-based platform for dialogue, information sharing and trust building to be set up by the European Commission that brings together the EU Member States, industry, public researchers, academia and civil society;

    ■ a risk-proportionate, predictable, science-based and non-discriminatory application of existing policy approaches allowing innovation to benefit European society and the environment.

    We stand ready to contribute to these efforts with our broad expertise in genome editing as it applies to healthcare, bio-economy and agriculture.

    Download the file below to read the full position paper.

    Achieving the Potential of Genome Editing: the Perspective of the European Biotech Industry


    Download
    2019_06_G_PP_EuropaBio-Updated-genome-editing-paperDownload
    Share
    Communications Team
    Communications Team

    Related posts

    03/04/2026

    Pivot Bio joins EuropaBio: Advancing Innovation in Sustainable Agriculture


    Read more
    02/04/2026

    The EU Biotech Act II: A vital Act for biomanufacturing in Europe


    Read more
    31/03/2026

    Nestlé joins EuropaBio: Driving Innovation for Sustainable Food Systems


    Read more

    Important links

    • Pivot Bio joins EuropaBio: Advancing Innovation in Sustainable Agriculture
    • The EU Biotech Act II: A vital Act for biomanufacturing in Europe

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.